Imd-0354

Imd-0354

SCHEMBL129165

O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

IKBKB

The experimentally established mechanism targets of Imd-0354. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
IKBKB known ✓ O14920 1/20 1.00
TMPRSS4 Q9NRS4 16/20 1.00
P2RX1 P51575 12/20 1.00
P2RX4 Q99571 8/20 1.00
P2RX7 Q99572 8/20 1.00
MEN1 O00255 1/20 1.00
CHUK O15111 1/20 1.00
KDR P35968 1/20 1.00
FLT3 P36888 1/20 1.00
KMT2A Q03164 1/20 1.00
MYLK Q15746 1/20 1.00
MAP4K5 Q9Y4K4 1/20 1.00
SLC2A1 P11166 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Imd-0354 SCHEMBL29406220 1.00 TMPRSS4 (1.00) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL13812702 0.97 TMPRSS4 (0.94) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL330059 0.94 TMPRSS4 (0.90) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL16707254 0.94 TMPRSS4 (0.88) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL131758 0.92 TMPRSS4 (0.85) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL30100386 0.92 TMPRSS4 (0.85) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL30100462 0.92 TMPRSS4 (0.85) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL14885966 0.91 TMPRSS4 (1.00) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL13189554 0.91 TMPRSS4 (0.83) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL30087037 0.90 TMPRSS4 (0.81) TMPRSS4P2RX1P2RX4P2RX7MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250082652-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES UNIVERSITÄT ZU KÖLN (DE) 2025-03-13 US claimed
EP-4460301-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES Universität zu Köln (DE) 2024-11-13 EP claimed
EP-3720493-B1 COMBINATIONS OF RIPK1- AND IKK-INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES UNIV KOELN (DE) 2024-07-24 EP claimed
CN-117337182-A Pharmaceutical composition of aquaporin inhibitor and preparation method thereof 江苏先声药业有限公司 2024-01-02 CN claimed
US-11801254-B2 Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate AEROMICS, INC. (US) 2023-10-31 US claimed
US-20230293556-A1 PHARMACEUTICAL COMPOSITION OF AQUAPORIN INHIBITOR AND PREPARATION METHOD THEREOF JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. (CN) 2023-09-21 US claimed
WO-2023131576-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES UNIVERSITÄT ZU KÖLN (DE) 2023-07-13 WO claimed
EP-4209213-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES Universität zu Köln (DE) 2023-07-12 EP claimed
EP-4192442-A1 PHARMACEUTICAL COMPOSITION OF AQUAPORIN INHIBITOR AND PREPARATION METHOD THEREOF Jiangsu Simcere Pharmaceutical Co., Ltd. (CN) 2023-06-14 EP claimed
US-20220249504-A1 LONGEVITY SIGNATURES AND THEIR APPLICATIONS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2022-08-11 US claimed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US claimed
EP-1352650-B1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES INST MED MOLECULAR DESIGN INC (JP) 2012-03-07 EP claimed
WO-2012019284-A1 COMBINATORY CANCER TREATMENT UNIVERSITE DE MONTREAL (CA) 2012-02-16 WO claimed
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 US claimed
US-20080249071-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-10-09 US claimed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US claimed
US-20060122243-A1 Antiallergic INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2006-06-08 US claimed
EP-1514544-A1 ANTIALLERGIC Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-16 EP claimed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 US claimed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11801254-B2 Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate PLCG2, DCTPP1, PLCG1 IKBKB 4164/4885TMPRSS4 1479/4885P2RX1 790/4885
US-20080090779-A1 ANTIALLERGIC AGENTS NAT1, EPX, HRH2 IKBKB 626/4885TMPRSS4 4322/4885P2RX1 2484/4885
US-20060122243-A1 Antiallergic EPX, NAT1, HNMT IKBKB 645/4885TMPRSS4 4304/4885P2RX1 2927/4885
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A IKBKB 9/4885TMPRSS4 1647/4885P2RX1 1538/4885
US-20080249071-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A IKBKB 9/4885TMPRSS4 1647/4885P2RX1 1538/4885
US-20230293556-A1 PHARMACEUTICAL COMPOSITION OF AQUAPORIN INHIBITOR AND PREPARATION METHOD THEREOF AQP1, AQP4, AQP3 IKBKB 1654/4885TMPRSS4 2849/4885P2RX1 588/4885
US-20220249504-A1 LONGEVITY SIGNATURES AND THEIR APPLICATIONS GLA, LIMS1, GLB1 IKBKB 2782/4885TMPRSS4 4552/4885P2RX1 4382/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB IKBKB 3/4885TMPRSS4 3292/4885P2RX1 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.